Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Rozita Yarmand on Tumor Suppressor Gene in Medullary Thyroid Cancer

February 15th 2017

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses how ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer.

Dr. Weiss on Biomarkers in Head and Neck Cancer

February 14th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses biomarkers in head and neck cancer.

Individualized Bioselection Treatment Methods Increase Survival Rates in Laryngeal Cancer

February 13th 2017

Gregory T. Wolf, MD, discusses a novel approach to treating patients with advanced laryngeal cancer.

Jena French on Combinations With Immunotherapy in Thyroid Cancer

February 7th 2017

Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.

Dr. Weiss on Next Steps for Immunotherapy in Head and Neck Cancer

February 4th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses next steps for immunotherapy agents in the treatment of patients with head and neck cancer.

Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer

February 2nd 2017

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.

Expert Discusses Updated HPV Vaccine Recommendations

January 26th 2017

Lois Ramondetta, MD, discusses the updated recommendations and the importance of advocating for lesser-known HPV-associated cancers.

Dr. Seiwert on Next Steps in Treatment of Patients With Head and Neck Cancer

January 24th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

Dr. Koyfman on the Evolution of Reirradiation Treatment in Head and Neck Cancer

January 19th 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses recent advancements in reirradiation treatment for patients with head and neck cancer.

Dr. Vokes on Recent Progress in the Treatment Landscape of Head and Neck Cancer

January 19th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses recent progress in the treatment landscape of head and neck cancer.

Dr. Dadu on Immunotherapy in Thyroid Cancer

January 14th 2017

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy to treat patients with thyroid cancer.

Novel Biomarker May Predict Recurrence in HPV+ Oropharyngeal Cancer

January 14th 2017

In the current treatment landscape of HPV-positive oropharyngeal squamous cell carcinoma, there is a significant lack of biomarkers to predict recurrence.

Robotic Surgery Represents a Notable Advance in Thyroid Cancer Care

January 13th 2017

Amid a rising incidence of thyroid cancer, endocrine surgeons have increasingly explored minimally invasive approaches for operating on patients with the disease.

Reduced-Dose Radiation Effective in HPV-Associated Oropharynx Cancers

January 6th 2017

Induction chemotherapy followed by reduced-dose radiation and weekly cetuximab demonstrated improved swallowing and nutritional status as well as an excellent complete clinical response for patients with HPV-associated oropharyngeal squamous cell carcinoma.

Dr. Vokes on Moving Immunotherapy into Frontline for Head and Neck Cancer

January 6th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the possibility of moving immunotherapy agents into the frontline setting for patients with head and neck cancer.

Immunotherapies Form New Frontier in Treating Head and Neck Cancers

January 2nd 2017

In August 2016, the FDA approved pembrolizumab for patients with platinum-refractory squamous cell carcinoma of the head and neck. Not only was it the first immunotherapy approved for head and neck cancer (HNC), but it marked the first new drug approval for HNC in the United States in 20 years.

Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

December 28th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Dr. Burtness on Treatment Approaches in HPV-Positive Head and Neck Cancer

December 27th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Distinct, Aggressive Subgroup of ACC Identified With Activating NOTCH1 Mutations

December 23rd 2016

NOTCH1 mutations have been found to define an aggressive subgroup of patients with adenoid cystic carcinomas, with a corresponding pattern of metastatic spread.

Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer

December 23rd 2016

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.